• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RILOTUMUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • RILOTUMUMAB chembl:CHEMBL1743063 Antineoplastic

    Alternate Names:

    RILOTUMUMAB
    AMG-102

    Drug Info:

    Pharmaceutical Developer Amgen
    Source Reported Drug Name(s) AMG 102/Rilotumumab
    Drug Class Monoclonal Antibody
    FDA Approval not approved
    Drug Indications antineoplastic agent
    Drug Class Therapeutic Antibodies
    (3 More Sources)

    Publications:

    Van Cutsem et al., 2014, Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer., Clin. Cancer Res.
  • RILOTUMUMAB   HGF

    Interaction Score: 8.35

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name AMG-102
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    CancerCommons TdgClinicalTrial TALC MyCancerGenome ChemblInteractions

  • RILOTUMUMAB   KRAS

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Rilotumumab + Panitumumab
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    24919569


    Sources:
    JAX-CKB

  • CancerCommons: AMG 102

    • Version: 25-July-2013

    Alternate Names:
    Rilotumumab Drug Trade Name
    AMG 102 Drug Development Name

    Drug Info:
    Drug Class Monoclonal Antibody
    Source Reported Drug Name(s) AMG 102/Rilotumumab
    Pharmaceutical Developer Amgen

    Publications:

  • MyCancerGenome: RILOTUMUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    AMG102 Development Name
    RILOTUMUMAB Generic Name

    Drug Info:
    Drug Class Therapeutic Antibodies

    Publications:

  • TdgClinicalTrial: AMG-102

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class monoclonal antibody
    FDA Approval not approved

    Publications:

  • JAX-CKB: Rilotumumab

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Van Cutsem et al., 2014, Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer., Clin. Cancer Res.

  • TALC: RILOTUMUMAB

    • Version: 12-May-2016

    Alternate Names:
    RILOTUMUMAB Primary Drug Name
    RILOTUMUMAB Drug Generic Name
    AMG 102 Drug Synonym

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1743063

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1743063

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21